Comparison of the effectiveness, safety, and costs of anti-Parkinson drugs: A multiple-center retrospective study.

ABSTRACT:

Aims

This study aimed to systematically compare the effectiveness, safety, and costs of different anti-Parkinson drugs (APDs).

Methods

This is a multi-center study that retrospectively analyzed the data of 8420 outpatients with PD from 2014 to 2019 across 30 tertiary hospitals in China. The effectiveness was evaluated by changes in total dosages of APDs, normalized by levodopa equivalent dose (LED) and presented as ΔLEDs; levodopa equivalent dose cost (LEDc) represented the daily cost of APDs; and newly added diagnostics were represented as APDs-related adverse events.

Results

A total of 384 patients with eligible medical records for three consecutive years were enrolled. Patients treated with carbidopa/levodopa or levodopa/benserazide had significantly lower mean ΔLE

SUBMITTER: Li W 

PROVIDER: S-EPMC11017413 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature